Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00694967 · ClinicalTrials.gov registry record · NA
A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix
A NA study, sponsored by Lehigh Valley Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 92
- Enrollment target
NCT00694967: Clinical Trial NA study, sponsored by Lehigh Valley Hospital.
NCT00694967 is a NA study that was terminated before completion, run by Lehigh Valley Hospital. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00694967, a NA study, was terminated before completion, sponsored by Lehigh Valley Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
Study Summary
We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to cerclage therapy. The purpose of this study was to compare medical therapy with 17P to surgical therapy with transvaginal cerclage in patients with an ultrasound diagnosed short cervix and funnel in the mid-trimester.
Interventions
- PROCEDURE McDonald cerclage placement
- DRUG 17 hydroxyprogesterone caproate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-12 |
| Phase | NA |
Why NCT00694967 stopped before completion
NCT00694967 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which McDonald cerclage placement is the first listed.
NCT00694967 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00694967 about?
NCT00694967 is a clinical study titled "A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix". We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to cerclage therapy. The purpose of this study was to compare medical therapy with 17P to surgical therapy with tra...
What is the current status of trial NCT00694967?
This trial is currently terminated. It is a NA study. The enrollment target is 92 participants. The study started on 2003-11. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00694967?
The interventions under investigation include: McDonald cerclage placement (PROCEDURE), 17 hydroxyprogesterone caproate (DRUG).
Who is sponsoring clinical trial NCT00694967?
This trial is sponsored by Lehigh Valley Hospital, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00694967's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia